Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review.
adverse effects
immune checkpoint inhibitors
ipilimumab
nivolumab
pembrolizumab
skin toxicity
Journal
Dermatology practical & conceptual
ISSN: 2160-9381
Titre abrégé: Dermatol Pract Concept
Pays: Austria
ID NLM: 101585990
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
accepted:
28
09
2020
entrez:
22
2
2021
pubmed:
23
2
2021
medline:
23
2
2021
Statut:
epublish
Résumé
Immune checkpoints assist with self-tolerance and minimize collateral tissue damage when immune responses are activated. Although immune checkpoint inhibitors (CPIs) are characterized by a favorable risk/benefit ratio, immune checkpoint blockade has been associated with a new subset of autoimmune-like toxicities, named immune-related adverse events (irAEs). Dermatologic reactions are among the most prevalent irAEs triggered by CPIs. In a majority of cases they are self-limiting and readily manageable. However, it is not uncommon that they result in severe skin involvement and impairment of patients' quality of life. Awareness of the spectrum of cutaneous irAEs is mandatory for every clinician involved in the management of oncologic patients. The role of the dermatologists is essential because early recognition and appropriate management of skin toxicity may prevent dose modifications and discontinuation of CPIs. The latter is particularly relevant, considering that recent data suggest favorable oncologic response in patients developing irAEs.
Identifiants
pubmed: 33614223
doi: 10.5826/dpc.1101a155
pii: dp1101a155
pmc: PMC7875661
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e2021155Informations de copyright
©2021 Apalla et al.
Déclaration de conflit d'intérêts
Competing interests: The authors have no conflicts of interest to disclose.
Références
Eur J Cancer. 2016 Jun;60:12-25
pubmed: 27043866
J Oncol Pharm Pract. 2019 Dec;25(8):2052-2055
pubmed: 30782092
JAAD Case Rep. 2017 Mar 02;3(2):90-92
pubmed: 28280766
JAMA Dermatol. 2015 Feb;151(2):195-9
pubmed: 25321335
Semin Immunopathol. 2016 Jan;38(1):11-27
pubmed: 26573299
J Am Acad Dermatol. 2020 May 13;:
pubmed: 32413449
Curr Opin Oncol. 2016 Jul;28(4):254-63
pubmed: 27136138
J Am Acad Dermatol. 2013 Nov;69(5):e272-e273
pubmed: 24124863
Eur J Cancer. 2019 Mar;110:107-109
pubmed: 30785013
JAMA Dermatol. 2016 Jan;152(1):45-51
pubmed: 26501224
Lung Cancer. 2017 Jul;109:42-44
pubmed: 28577948
Int J Dermatol. 2018 Jun;57(6):664-669
pubmed: 29630716
Ann Rheum Dis. 2017 Jan;76(1):43-50
pubmed: 27307501
J Eur Acad Dermatol Venereol. 2017 Sep;31 Suppl 5:3-7
pubmed: 28805939
Cancer Immunol Res. 2016 May;4(5):383-9
pubmed: 26928461
Autoimmune Dis. 2019 Jun 9;2019:7595706
pubmed: 31308976
Acta Derm Venereol. 2016 Feb;96(2):259-60
pubmed: 26270860
BMC Cancer. 2017 May 12;17(1):327
pubmed: 28499411
J Am Acad Dermatol. 2020 Mar;82(3):770-772
pubmed: 31734192
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
J Cutan Pathol. 2017 Feb;44(2):158-176
pubmed: 27859479
Cancer Treat Rev. 2017 Jun;57:36-49
pubmed: 28550712
J Natl Compr Canc Netw. 2020 Mar;18(3):230-241
pubmed: 32135517
Br J Dermatol. 2017 Jun;176(6):1649-1652
pubmed: 27943234
Int J Dermatol. 2017 May;56(5):527-533
pubmed: 28188628
J Immunother Cancer. 2016 Sep 20;4:55
pubmed: 27660709
Ann Oncol. 2017 Feb 1;28(2):368-376
pubmed: 27687304
J Investig Med High Impact Case Rep. 2016 Oct 25;4(4):2324709616674316
pubmed: 27826593
N Engl J Med. 1994 Nov 10;331(19):1272-85
pubmed: 7794310
Dermatol Ther. 2016 Sep;29(5):306-308
pubmed: 27357143
Melanoma Res. 2016 Aug;26(4):417-20
pubmed: 27031538
N Engl J Med. 2011 Jul 21;365(3):231-8
pubmed: 21774711
Melanoma Res. 2013 Dec;23(6):498-501
pubmed: 24113862
Future Oncol. 2017 Aug;13(18):1607-1618
pubmed: 28835114
JAAD Case Rep. 2017 Apr 14;3(3):208-211
pubmed: 28443311
Acta Derm Venereol. 2017 Apr 6;97(4):539-540
pubmed: 27826614
J Am Acad Dermatol. 2019 Apr;80(4):990-997
pubmed: 30399387
N Engl J Med. 2015 May 21;372(21):2006-17
pubmed: 25891304
J Immunother. 2020 Apr;43(3):89-92
pubmed: 31651559
Clin Cancer Res. 2016 Feb 15;22(4):886-94
pubmed: 26446948
Ann Oncol. 2015 Dec;26(12):2375-91
pubmed: 26371282
Acta Med Port. 2020 May 4;33(5):335-343
pubmed: 32416756
JAAD Case Rep. 2016 Jul 14;2(3):264-8
pubmed: 27486590
Oncotarget. 2015 Feb 28;6(6):3479-92
pubmed: 25682878
J Immunother Cancer. 2017 Nov 21;5(1):95
pubmed: 29162153
J Am Acad Dermatol. 2018 Dec;79(6):1081-1088
pubmed: 30025829
Int J Dermatol. 2012 Oct;51(10):1199-205
pubmed: 22416968
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
J Eur Acad Dermatol Venereol. 2018 Jul;32(7):e256-e257
pubmed: 28430376
Support Care Cancer. 2020 Dec;28(12):5597-5599
pubmed: 32827054
J Clin Oncol. 2015 Mar 1;33(7):773-81
pubmed: 25605840
Lancet. 2017 Jan 7;389(10064):67-76
pubmed: 27939400
Oncologist. 2015 Jul;20(7):812-22
pubmed: 26069281
Br J Dermatol. 2018 Jan;178(1):265-269
pubmed: 28132411
J Dermatol. 2017 Feb;44(2):117-122
pubmed: 27510892
Br J Dermatol. 2014 Nov;171(5):1236-7
pubmed: 24749658
J Clin Oncol. 2012 Jul 20;30(21):2691-7
pubmed: 22614989
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
J Am Acad Dermatol. 2021 Feb;84(2):540-543
pubmed: 32428613
Melanoma Res. 2017 Jun;27(3):271-273
pubmed: 28146044
Dermatol Ther. 2019 Sep;32(5):e13074
pubmed: 31444856
J Dermatol. 2019 Nov;46(11):e434-e436
pubmed: 31342541
J Eur Acad Dermatol Venereol. 2017 May;31(5):e254-e257
pubmed: 27739129
J Am Acad Dermatol. 2016 Mar;74(3):455-61.e1
pubmed: 26793994
Ann Rheum Dis. 2018 Mar;77(3):468-470
pubmed: 28242618
Am J Dermatopathol. 2017 Feb;39(2):121-129
pubmed: 28134729
Eur J Dermatol. 2016 Jun 1;26(3):320-1
pubmed: 27210586